Seksyen 1
Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) (No. 2) 2023.
/akn/my/act/pua/2023/306
PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023
The full official text, structured for quick navigation. Copy any provision or jump straight to a section.
- Type
- P.U. (A)
- Status
- In force
- Enacted
- 2023
- Sections
- 2
Quick answer
About this p.u. (a)
PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 is Malaysia P.U. (A), cited as P.U. (A) 306 2023, currently marked in force and first recorded in 2023.
Opening note
Preamble
- PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama
Seksyen 2
Pindaan Jadual Pertama
(i)
dengan memasukkan selepas butiran “Abiraterone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Bahagian I
Part I
Bahagian II
Part II
Exempt
Group A
Group B
Group C
Group D
“Acalabrutinib
-
All preparations”;
P.U. (A) 306 3
(ii)
dengan menggantikan butiran “Amfepramone; its salts” dengan butiran “Amfepramone”;
(iii)
dengan menggantikan butiran “Aminorex; its salts” dengan butiran “Aminorex”;
(iv)
dengan memasukkan selepas butiran “Avanafil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Avelumab
-
All preparations”;
(v)
dengan menggantikan butiran “Barbituric acid and other substances structurally derived therefrom;
their compounds; their salts” dengan butiran “Barbituric acid”;
(vi)
dengan memasukkan selepas butiran “Benzoctamine; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 4
Names
Exempt
Group A
Group B
Group C
Group D
“1,4-Benzodiazepine unless specified elsewhere in the List
-
All preparations”;
(vii)
dengan menggantikan butiran “Benzphetamine; its salts” dengan butiran “Benzphetamine”;
(viii)
dengan menggantikan butiran “2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25B-NBOMe)”
dengan butiran “2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)”;
(ix)
dengan menggantikan butiran “Buprenorphine; its salts” dengan butiran “Buprenorphine”;
(x)
dengan memasukkan selepas butiran “Butropium; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 5
Names
Exempt
Group A
Group B
Group C
Group D
“Tert-Butyl 4-
(phenylamino)piperidine-1-
carboxylate (1-boc-4-AP)
-
-
-
All preparations”;
(xi)
dengan memasukkan selepas butiran “Candesartan; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Cannabidiol
-
All preparations”;
(xii)
dengan memasukkan selepas butiran “Capecitabine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Capmatinib
-
All preparations”;
P.U. (A) 306 6
(xiii)
dengan menggantikan butiran “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25C-NBOMe)”
dengan butiran “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;
(xiv)
dengan memotong butiran “Diazepam and other substances structurally derived from 1, 4-benzodiazepine;
their salts, unless specified elsewhere in the List” dan butir-butir yang berhubungan dengannya;
(xv)
dengan memasukkan selepas butiran “Dinitrothymols” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Diphenidine
-
All preparations”;
(xvi)
dengan memasukkan selepas butiran “Disodium clodronate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 7
Names
Exempt
Group A
Group B
Group C
Group D
“Disodium edetate
-
-
All preparations for parenteral administration
-
-
All preparations unless in Group C”;
(xvii)
dengan memasukkan selepas butiran “Entecavir” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Entrectinib
-
All preparations”;
(xviii)
dengan memasukkan selepas butiran “Erythropoietin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Esafoxolaner
-
All preparations”;
P.U. (A) 306 8
(xix)
dengan menggantikan butiran “N-Ethylamphetamine; its salts” dengan butiran “Ethylamphetamine”;
(xx)
dengan memasukkan selepas butiran “Etryptamine; its salts (DD)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Eutylone (DD)
-
All preparations”;
(xxi)
dengan menggantikan butiran “Fluorides, alkali; organo fluorides” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Fluorides, alkali; organo fluorides
-
-
All medicinal preparations containing 3% and over 3% and over
Sodium
Silicofluoride or
Sodium Fluoride unless in Group C
-
All preparations other than those in Group C or
Group D”;
P.U. (A) 306 9
(xxii)
dengan memasukkan selepas butiran “Granisetron; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Grapiprant
-
All preparations”;
(xxiii)
dengan memasukkan selepas butiran “Imiquimod” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Inclisiran
-
All preparations”;
(xxiv)
dengan menggantikan butiran “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)”
dengan butiran “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;
(xxv)
dengan memasukkan selepas butiran “Labetalol; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 10
Names
Exempt
Group A
Group B
Group C
Group D
“Labuvirtide
-
All preparations”;
(xxvi)
dengan menggantikan butiran “Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane” dengan butiran
“Lefetamine”;
(xxvii)
dengan memasukkan selepas butiran “Leflunomide; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Lemborexant
-
All preparations”;
(xxviii)
dengan memasukkan selepas butiran “Lung Phospholipid” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Lurasidone
-
All preparations”;
P.U. (A) 306 11
(xxix)
dengan memasukkan selepas butiran “Luseogliflozin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Luspatercept
-
All preparations”;
(xxx)
dengan memasukkan selepas butiran “5-Methoxy-N,N-methylisopropyltryptamine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“3-Methoxyphencyclidine
(3-MeO-PCP)
-
All preparations”;
(xxxi)
dengan memasukkan selepas butiran “4-Methylbuphedrone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 12
Names
Exempt
Group A
Group B
Group C
Group D
“Methyl 3, 3-dimethyl-2-(1-
(pent-4-en-1-yl)-1H-indazole-
3-carboxamido)butanoate
(MDMB-4en-PINACA) (DD)
-
All preparations”;
(2S)
-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-
dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)” dan butir-butir yang berhubungan dengannya;
(xxxiii)
dengan memasukkan selepas butiran “4-Methylethcathinone (4-MEC)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Methyl (2S)-2-{[1 -
(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-
3,3- dimethylbutanoate
(5F-ADB/ 5F-MDMB-PINACA) (DD)
-
All preparations”;
P.U. (A) 306 13
(xxxiv)
dengan memotong butiran “3-Methylmethcathinone (3-MMC)” dan butir-butir yang berhubungan dengannya;
(2S)
-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-
methylbutanoate (AMB-FUBINACA)” dan butir-butir yang berhubungan dengannya;
(xxxvi)
dengan memasukkan selepas butiran “3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“3-Methylmethcathinone
(3-MMC)
-
All preparations”;
(xxxvii)
dengan menggantikan butiran “Methylphenidate; its salts” dengan butiran “Methylphenidate”;
(xxxviii)
xxxviii
dengan memasukkan selepas butiran “Mofebutazone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 14
Names
Exempt
Group A
Group B
Group C
Group D
“Molnupiravir
-
All preparations”;
(xxxix)
dalam senarai “Monoclonal antibody; includes the following:”—
dengan memasukkan selepas butiran “Brolucizumab” butiran “Burosumab”;
dengan memasukkan selepas butiran “Canakinumab” butiran “Casirivimab”;
dengan memasukkan selepas butiran “Evolocumab” butiran “Faricimab”;
dengan memasukkan selepas butiran “Idarucizumab” butiran “Imdevimab”;
dengan memasukkan selepas butiran “Ranibizumab” butiran “Regdanvimab”;
dengan memasukkan selepas butiran “Sarilumab” butiran “Satralizumab”; dan dengan memasukkan selepas butiran “Siltuximab” butiran “Sotrovimab”;
(xl)
dengan menggantikan butiran “Nalbuphine; its salts” dengan butiran “Nalbuphine”:
P.U. (A) 306 15
(xli)
dalam senarai “Narcotic substances; the following:”—
dengan memasukkan selepas butiran “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
dengan memasukkan selepas butiran “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)”
dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
dengan memasukkan selepas butiran “(DD) Isomethadone” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“(DD) Brorphine
-
All preparations”;
Names
Bahagian II
Part II Exempt
Group A
Group B
Group C
Group D
“(DD) Metonitazene
-
All preparations”; dan
P.U. (A) 306 16
(xlii)
dengan memasukkan selepas butiran “Nintedanib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Nirmatrelvir
-
All preparations”;
(xliii)
dengan menggantikan butiran “Nitric Oxide” dan butir-butir yang berhubungan dengannya dengan butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“(DD) Isotonitazene
-
All preparations”;
P.U. (A) 306 17
Names
Exempt
Group A
Group B
Group C
Group D
“Nitric Oxide
-
Preparations in the form of medicinal gas for therapeutic use
-
-
-
(2)
Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;
(xliv)
dengan memasukkan selepas butiran “Norephedrine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 18
Names
Exempt
Group A
Group B
Group C
Group D
“Norfentanyl
-
-
-
All preparations”;
(xlv)
dengan memasukkan selepas butiran “Nortriptyline; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Nusinersen
-
All preparations”;
(xlvi)
dengan memasukkan selepas butiran “Nystatin” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Oclacitinib
-
All preparations”;
(xlvii)
dengan memasukkan selepas butiran “Pegabtanib Sodium” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 19
Names
Exempt
Group A
Group B
Group C
Group D
“Pegaspargase
-
All preparations”;
(xlviii)
dengan memasukkan selepas butiran “Pegvisomant” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Pemafibrate
-
All preparations”;
(xlix)
dengan menggantikan butiran “Pemoline; its salts” dengan butiran “Pemoline”;
(l)
dengan menggantikan butiran “Pentazocine; its salts” dengan butiran “Pentazocine”;
(li)
dengan memasukkan selepas butiran
“(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
(UR-144) (DD)” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 20
Names
Exempt
Group A
Group B
Group C
Group D
“5-Pentyl-2-(2-phenylpropan-
2-yl)-2,5-dihydro-1H-pyrido
[4,3-b]indol-1-one
(CUMYL-PEGACLONE)(DD)
-
All preparations”;
(lii)
dengan menggantikan butiran “Phencyclidine; its salts” dengan butiran “Phencyclidine”;
(liii)
dengan menggantikan butiran “Phendimetrazine; its salts” dengan butiran “Phendimetrazine”;
(liv)
dengan menggantikan butiran “Phenmetrazine; its salts” dengan butiran “Phenmetrazine”;
(lv)
dengan menggantikan butiran “Phentermine; its salts” dengan butiran “Phentermine”;
(lvi)
dengan memasukkan selepas butiran “Phenylene-1, 4-diisothiocyanate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 21
Names
Exempt
Group A
Group B
Group C
Group D
“N-Phenyl-4-piperidinamine
(4-AP)
-
-
-
All preparations”;
(lvii)
dengan memasukkan selepas butiran “Pimecrolimus” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Pimobendan
-
All preparations”;
(lviii)
dengan menggantikan butiran “Piperidine” dengan butiran “Piperidine unless specified elsewhere in the List”;
(lix)
dengan menggantikan butiran “Pipradrol; its salts” dengan butiran “Pipradrol”;
(lx)
dengan memasukkan selepas butiran “Plerixafor” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 22
Names
Exempt
Group A
Group B
Group C
Group D
“Polidocanol
-
All preparations for parenteral administration
-
-
-
All preparations unless in Group B”;
(lxi)
dengan memasukkan selepas butiran “Propantheline; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Propiverine
-
All preparations”;
(lxii)
dengan menggantikan butiran “Propylhexedrine; its salts” dengan butiran “Propylhexedrine”;
(lxiii)
dengan memasukkan selepas butiran “Rasburicase” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Ravidasvir
-
All preparations”;
P.U. (A) 306 23
(lxiv)
dengan memasukkan selepas butiran “Rizatriptan; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Robenacoxib
-
All preparations”;
(lxv)
dengan memasukkan selepas butiran “Sacubitril” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Safinamide
-
All preparations”;
(lxvi)
dengan memasukkan selepas butiran “Saquinavir; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Sarolaner
-
All preparations”;
P.U. (A) 306 24
(lxvii)
dengan memotong butiran “Sodium edetate” dan butir-butir yang berhubungan dengannya;
(lxviii)
dengan memasukkan selepas butiran “Sodium hydroxide” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Sodium zirconium cyclosilicate
-
All preparations”;
(lxix)
dengan memasukkan selepas butiran “Tadalafil” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Tafamidis
-
All preparations”;
(lxx)
dengan memasukkan selepas butiran “Tafluprost” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 25
Names
Exempt
Group A
Group B
Group C
Group D
“Talazoparib
-
All preparations”;
(lxxi)
dengan memasukkan selepas butiran “Tetramisole” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Tetrofosmin
-
-
All preparations for parenteral administration
-
-
All preparations unless in Group C”;
(lxxii)
dengan memasukkan selepas butiran “Toltrazuril” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Tolvaptan
-
All preparations”;
(lxxiii)
dengan memasukkan selepas butiran “Valaciclovir; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 306 26
Names
Exempt
Group A
Group B
Group C
Group D
“Valbenazine
-
All preparations”;
(lxxiv)
dengan memasukkan selepas butiran “Verapamil; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Vericiguat
-
All preparations”;
(lxxv)
dengan menggantikan butiran “Zinc p-phenolsulphonate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Zinc p-phenolsulphonate
-
-
Medicinal preparations unless exempted
All preparations other than
Group C and exempted
-
Strength of 5%
and under”;
P.U. (A) 306 27
(lxxvi)
dengan menggantikan butiran “Zipeprol; its salts” dengan butiran “Zipeprol”; dan
(lxxvii)
dengan menggantikan butiran “Zolpidem; its salts” dengan butiran “Zolpidem”; dan
(i)
dalam senarai “Anaesthetics:”—
dengan memasukkan selepas butiran “Desflurane” butiran “Diphenidine”;
dengan memasukkan selepas butiran “Methoxetamine (MXE)” butiran “3-Methoxyphencyclidine
(3-MeO-PCP)”; dan dengan menggantikan butiran “Phencyclidine; its salts” dengan butiran “Phencyclidine”;
(ii)
dalam senarai “Analeptics and Central Stimulants:”—
dengan menggantikan butiran “N-Ethylamphetamine; its salts” dengan butiran “Ethylamphetamine”;
dengan memasukkan selepas butiran “Etryptamine (DD)” butiran “Eutylone (DD)”;
P.U. (A) 306 28
dengan menggantikan butiran “Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane”
dengan butiran “Lefetamine”;
dengan memasukkan selepas butiran “4-Methylbuphedrone” butiran “Methyl 3,3-dimethyl-2-(1-(pent-4-en-
1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)”;
dengan menggantikan butiran
“Methyl
(2S)
-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carbonyl}amino)-3-methylbutanoate
(AMB-FUBINACA)”
dengan butiran
“Methyl
(2S)
-2-({1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
dengan menggantikan butiran “Methylphenidate; its salts” dengan butiran “Methylphenidate”;
dengan menggantikan butiran “Pemoline; its salts” dengan butiran “Pemoline”; dan dengan menggantikan butiran “Pipradrol; its salts” dengan butiran “Pipradrol”;
(iii)
dalam senarai “Analgesics including antipyretic and anti-inflammatory agents:”—
dengan menggantikan butiran “Buprenorphine; its salts” dengan butiran “Buprenorphine”;
dengan memasukkan selepas butiran “Glaphenine” butiran “Grapiprant”;
P.U. (A) 306 29
dengan menggantikan butiran “Nalbuphine; its salts” dengan butiran “Nalbuphine”;
dengan menggantikan butiran “Pentazocine; its salts” dengan butiran “Pentazocine”; dan dengan memasukkan selepas butiran “Rizatriptan; its salts” butiran “Robenacoxib”;
(iv)
dalam senarai “Anorectics:”—
dengan menggantikan butiran “Amfepramone; its salts” dengan butiran “Amfepramone”;
dengan menggantikan butiran “Aminorex; its salts” dengan butiran “Aminorex”;
dengan menggantikan butiran “Benzphetamine; its salts” dengan butiran “Benzphetamine”;
dengan menggantikan butiran “Phendimetrazine; its salts” dengan butiran “Phendimetrazine”;
dengan menggantikan butiran “Phenmetrazine; its salts” dengan butiran “Phenmetrazine”;
dengan menggantikan butiran “Phentermine; its salts” dengan butiran “Phentermine”; dan dengan menggantikan butiran “Propylhexedrine; its salts” dengan butiran “Propylhexedrine”;
P.U. (A) 306 30
(v)
dalam senarai
“Anticholinergics:”, dengan memasukkan selepas butiran
“Propantheline;
its salts”
butiran “Propiverine”;
(vi)
dalam senarai “Anticonvulsants:”, dengan memasukkan selepas butiran “Beclamide” butiran “Cannabidiol”;
(vii)
dalam senarai “Antineoplastic agents and Immunosuppressants:”—
dengan memasukkan selepas butiran “Abiraterone” butiran “Acalabrutinib”;
dengan memasukkan selepas butiran “Atezolizumab” butiran “Avelumab”;
dengan memasukkan selepas butiran “Capecitabine” butiran “Capmatinib”;
dengan memasukkan selepas butiran “Carmustine; its salts” butiran “Casirivimab”;
dengan memasukkan selepas butiran “Durvalumab” butiran “Entrectinib”;
dengan memasukkan selepas butiran “Idelalisib” butiran “Imdevimab”;
dengan memasukkan selepas butiran “Pazopanib” butiran “Pegaspargase”;
P.U. (A) 306 31
dengan memasukkan selepas butiran “Sarilumab” butiran “Satralizumab”; dan dengan memasukkan selepas butiran “Tacrolimus” butiran “Talazoparib”;
(viii)
dalam senarai “Antiparkinsonism agents:”, dengan memasukkan selepas butiran “Rotigotine” butiran
“Safinamide”;
(ix)
dalam senarai “Antiviral agents:”—
dengan memasukkan selepas butiran “Interferons” butiran “Labuvirtide”;
dengan memasukkan selepas butiran “Methisoprinol” butiran “Molnupiravir”;
dengan memasukkan selepas butiran “Nevirapine; its salts” butiran “Nirmatrelvir”;
dengan memasukkan selepas butiran “Pibrentasvir” butiran yang berikut:
“Ravidasvir
Regdanvimab”; dan
P.U. (A) 306 32
dengan memasukkan selepas butiran “Sofosbuvir” butiran “Sotrovimab”;
(x)
dalam senarai “Cardio drugs:”—
dengan memasukkan selepas butiran “Oxprenolol; its salts” butiran “Pimobendan”; dan dengan memasukkan selepas butiran “Tirofiban” butiran “Vericiguat”;
(xi)
dalam senarai “Dermatological agents:”, dengan memasukkan selepas butiran “Methoxsalen” butiran “Oclacitinib”;
(xii)
dalam senarai “Diuretics:”, dengan memasukkan selepas butiran “Spironolactone” butiran “Tolvaptan”;
(xiii)
dalam senarai “Hallucinogens:”—
dengan menggantikan butiran
“2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25B-NBOMe)”
dengan butiran
“2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25B-NBOMe) (DD)”;
dengan menggantikan butiran
“2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25C-NBOMe)”
dengan butiran
“2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25C-NBOMe) (DD)”; dan
P.U. (A) 306 33
dengan menggantikan butiran
“2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25I-NBOMe)”
dengan butiran
“2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25I-NBOMe) (DD)”;
(xiv)
dalam senarai “Hypnotics and sedatives:”—
dengan menggantikan butiran “Barbituric acid and other substances structurally derived therefrom;
their compounds; their salts” dengan butiran “Barbituric acid”;
dengan memasukkan selepas butiran “Hexapropymate” butiran “Lemborexant”; dan dengan menggantikan butiran “Zolpidem; its salts” dengan butiran “Zolpidem”;
(xv)
dalam senarai “Industrial and laboratory poisons:”, dengan menggantikan butiran “Piperidine” dengan butiran
“Piperidine unless specified elsewhere in the List”;
(xvi)
dalam senarai “Narcotics:”—
dengan memasukkan selepas butiran
“(DD)
4-bromo-2,
5-dimethoxyphenethylamine
(2C-B)”
butiran “(DD) Brorphine”;
P.U. (A) 306 34
dengan memasukkan selepas butiran “(DD) Isomethadone” butiran “(DD) Isotonitazene”; dan dengan memasukkan selepas butiran “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)”
butiran “(DD) Metonitazene”;
(xvii)
dalam senarai “Tranquillisers:”—
dengan memasukkan selepas butiran “Benzoctamine; its salts” butiran “1,4-Benzodiazepine unless specified elsewhere in the List”;
dengan memotong butiran “Diazepam and other substances structurally derived from 1, 4-benzodiazepine;
their salts, unless specified elsewhere in the List”;
dengan memasukkan selepas butiran “Hydroxyzine; its salts” butiran “Lurasidone”; dan dengan memasukkan selepas butiran “Tybamate” butiran “Valbenazine”; dan
(xviii)
dalam senarai “Miscellaneous:”—
dengan memasukkan selepas butiran “Brucine” butiran berikut:
P.U. (A) 306 35
“Burosumab
Tert-Butyl 4-
(phenylamino)piperidine-1-carboxylate (1-boc-4-AP)”;
dengan memasukkan selepas butiran “Disodium clodronate” butiran “Disodium edetate”;
dengan memasukkan selepas butiran “Ergot, alkaloids of” butiran “Esafoxolaner”;
dengan memasukkan selepas butiran “Fampridine” butiran “Faricimab”;
dengan memasukkan selepas butiran “Imiquimod” butiran “Inclisiran”;
dengan memasukkan selepas butiran “Lung phospholipid” butiran “Luspatercept”;
dengan memotong butiran “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-
methylbutanoate (FUB-AMB) (DD)”;
dengan memasukkan selepas butiran “Nitrophenols, ortho, meta and para” butiran berikut:
P.U. (A) 306 36
“Norfentanyl
Nusinersen”;
dengan memasukkan selepas butiran “Pegvisomant” butiran “Pemafibrate”;
(J)
dengan memasukkan selepas butiran “Pentosan” butiran “5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-
1H-pyrido[4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)”;
(K)
dengan memasukkan selepas butiran “Phenols (any member of the series of phenols of which the first member is phenol and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” butiran “N-Phenyl-4-piperidinamine
(4-AP)”;
(O)
dengan memasukkan selepas butiran “Sodium cromoglycate” butiran “Sodium zirconium cyclosilicate”;
P.U. (A) 306 37
(Q)
dengan memasukkan selepas butiran “Teriparatide” butiran “Tetrofosmin”.
Dibuat 13 September 2023
[KKM.600-18/2/95; PN(PU2)172/JLD. 20]
DR. ZALIHA BINTI MUSTAFA
Menteri Kesihatan
P.U. (A) 306 38
POISONS ACT 1952
POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2023
Opening note
Preamble
- IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) (No. 2) Order 2023. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule—
(i)
by inserting after the item “Abiraterone” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Acalabrutinib
-
All preparations”;
P.U. (A) 306 39
(ii)
by substituting for the item “Amfepramone; its salts” the item “Amfepramone”;
(iv)
by inserting after the item “Avanafil” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Avelumab
-
All preparations”;
(v)
by substituting for the item “Barbituric acid and other substances structurally derived therefrom; their compounds;
their salts” the item “Barbituric acid”;
(vi)
by inserting after the item “Benzoctamine; its salts” and the particulars relating to it the following item and particulars:
P.U. (A) 306 40
Names
Exempt
Group A
Group B
Group C
Group D
“1,4-Benzodiazepine unless specified elsewhere in the List
-
All preparations”;
(vii)
by substituting for the item “Benzphetamine; its salts” the item “Benzphetamine”;
(viii)
by substituting for the item “2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25B-NBOMe)”
the item “2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe) (DD)”;
(ix)
by substituting for the item “Buprenorphine; its salts” the item “Buprenorphine”;
(x)
by inserting after the item “Butropium; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tert-Butyl 4-
(phenylamino)piperidine-1-
carboxylate (1-boc-4-AP)
-
-
-
All preparations”;
P.U. (A) 306 41
(xi)
by inserting after the item “Candesartan; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Cannabidiol
-
All preparations”;
(xii)
by inserting after the item “Capecitabine” and particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Capmatinib
-
All preparations”;
(xiii)
by substituting for the item “2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine(25C-NBOMe)”
the item “2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe) (DD)”;
(xiv)
by deleting the item “Diazepam and other substances structurally derived from 1,4-benzodiazepine; their salts, unless specified elsewhere in the List” and the particulars relating to it;
(xv)
by inserting after the item “Dinitrothymols” and the particulars relating to it the following item and particulars:
P.U. (A) 306 42
Names
Exempt
Group A
Group B
Group C
Group D
“Diphenidine
-
All preparations”;
(xvi)
by inserting after the item “Disodium clodronate” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Disodium edetate
-
-
All preparations for parenteral administration
-
-
All preparations unless in Group C”;
(xvii)
by inserting after the item “Entecavir” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Entrectinib
-
All preparations”;
P.U. (A) 306 43
(xviii)
by inserting after the item “Erythropoietin” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Esafoxolaner
-
All preparations”;
(xix)
by substituting for the item “N-Ethylamphetamine; its salts” the item “Ethylamphetamine”;
(xx)
by inserting after the item “Etryptamine; its salts (DD)” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Eutylone (DD)
-
All preparations”;
P.U. (A) 306 44
(xxi)
by substituting for the item “Fluorides, alkali; organo fluorides” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Fluorides, alkali; organo fluorides
-
-
All medicinal preparations containing 3% and over 3% and over
Sodium
Silicofluoride or
Sodium Fluoride unless in Group C
-
All preparations other than those in Group C or
Group D”;
(xxii)
by inserting after the item “Granisetron; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Grapiprant
-
All preparations”;
P.U. (A) 306 45
(xxiii)
by inserting after the item “Imiquimod” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Inclisiran
-
All preparations”;
(xxiv)
by substituting for the item “2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)”
the item “2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) (DD)”;
(xxv)
by inserting after the item “Labetalol; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Labuvirtide
-
All preparations”;
(xxvi)
by substituting for the item “Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane” the item “Lefetamine”;
P.U. (A) 306 46
(xxvii)
by inserting after the item “Leflunomide; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Lemborexant
-
All preparations”;
(xxviii)
by inserting after the item “Lung Phospholipid” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Lurasidone
-
All preparations”;
(xxix)
by inserting after the item “Luseogliflozin” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Luspatercept
-
All preparations”;
P.U. (A) 306 47
(xxx)
by inserting after the item “5-Methoxy-N,N-methylisopropyltryptamine” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“3-Methoxyphencyclidine
(3-MeO-PCP)
-
All preparations”;
(xxxi)
by inserting after the item “4-Methylbuphedrone” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Methyl 3, 3-dimethyl-2-(1-
(pent-4-en-1-yl)-1H-indazole-
3-carboxamido)butanoate
(MDMB-4en-PINACA) (DD)
-
All preparations”;
(xxxii)
by deleting the item “Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
(5F-ADB/5F-MDMB-PINACA) (DD)” and the particulars relating to it;
P.U. (A) 306 48
(xxxiii)
by inserting after the item “4-Methylethcathinone (4-MEC)” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Methyl (2S)-2-{[1 -
(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-
3,3- dimethylbutanoate
(5F-ADB/ 5F-MDMB-PINACA) (DD)
-
All preparations”;
(xxxiv)
by deleting the item “3-Methylmethcathinone (3-MMC)” and the particulars relating to it;
(2S)
-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-
methylbutanoate (AMB-FUBINACA)” and the particulars relating to it;
(xxxvi)
by inserting after the item “3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)” and the particulars relating to it the following item and particulars:
P.U. (A) 306 49
Names
Exempt
Group A
Group B
Group C
Group D
“3-Methylmethcathinone
(3-MMC)
-
All preparations”;
(xxxvii)
by substituting for the item “Methylphenidate; its salts” the item “Methylphenidate”;
(xxxviii)
xxxviii
by inserting after the item “Mofebutazone” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Molnupiravir
-
All preparations”;
(xxxix)
in the list of “Monoclonal antibody; includes the following:”—
by inserting after the item “Brolucizumab” the item “Burosumab”;
by inserting after the item “Canakinumab” the item “Casirivimab”;
by inserting after the item “Evolocumab” the item “Faricimab”;
P.U. (A) 306 50
by inserting after the item “Idarucizumab” the item “Imdevimab”;
by inserting after the item “Ranibizumab” the item “Regdanvimab”;
by inserting after the item “Sarilumab” the item “Satralizumab”; and by inserting after the item “Siltuximab” the item “Sotrovimab”;
(xli)
in the list of “Narcotic substances; the following:”—
by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“(DD) Brorphine
-
All preparations”;
P.U. (A) 306 51
by inserting after the item “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” and the particulars relating to it the following item and particulars:
by inserting after the item “(DD) Isomethadone” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“(DD) Isotonitazene
-
All preparations”;
(xlii)
by inserting after the item “Nintedanib” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Nirmatrelvir
-
All preparations”;
Names
Group A
Group B
Group C
Group D
“(DD) Metonitazene
-
All preparations”; and
P.U. (A) 306 52
(xliii)
by substituting for the item “Nitric oxide” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Nitric Oxide
-
Preparations in the form of medicinal gas for therapeutic use
-
-
-
(2)
Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;
P.U. (A) 306 53
(xliv)
by inserting after the item “Norephedrine” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Norfentanyl
-
-
-
All preparations”;
(xlv)
by inserting after the item “Nortriptyline; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Nusinersen
-
All preparations”;
(xlvi)
by inserting after the item “Nystatin” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Oclacitinib
-
All preparations”;
P.U. (A) 306 54
(xlvii)
by inserting after the item “Pegabtanib Sodium” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Pegaspargase
-
All preparations”;
(xlviii)
by inserting after the item “Pegvisomant” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Pemafibrate
-
All preparations”;
(l)
by substituting for the item “Pentazocine; its salts” the item “Pentazocine”;
(li)
by inserting after the item “(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)”
and the particulars relating to it the following item and particulars:
P.U. (A) 306 55
Names
Exempt
Group A
Group B
Group C
Group D
“5-Pentyl-2-(2-phenylpropan-
2-yl)-2,5-dihydro-1H-pyrido
[4,3-b]indol-1-one
(CUMYL-PEGACLONE)(DD)
-
All preparations”;
(lii)
by substituting for the item “Phencyclidine; its salts” the item “Phencyclidine”;
(liii)
by substituting for the item “Phendimetrazine; its salts” the item “Phendimetrazine”;
(liv)
by substituting for the item “Phenmetrazine; its salts” the item “Phenmetrazine”;
(lv)
by substituting for the item “Phentermine; its salts” the item “Phentermine”;
(lvi)
by inserting after the item “Phenylene-1, 4-diisothiocyanate” and the particulars relating to it the following item and particulars:
P.U. (A) 306 56
Names
Exempt
Group A
Group B
Group C
Group D
“N-Phenyl-4-piperidinamine
(4-AP)
-
-
-
All preparations”;
(lvii)
by inserting after the item “Pimecrolimus” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Pimobendan
-
All preparations”;
(lviii)
by substituting for the item “Piperidine” the item “Piperidine unless specified elsewhere in the List”;
(lx)
by inserting after the item “Plerixafor” and the particulars relating to it the following item and particulars:
P.U. (A) 306 57
Names
Exempt
Group A
Group B
Group C
Group D
“Polidocanol
-
All preparations for parenteral administration
-
-
-
All preparations unless in Group B”;
(lxi)
by inserting after the item “Propantheline; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Propiverine
-
All preparations”;
(lxii)
by substituting for the item “Propylhexedrine; its salts” the item “Propylhexedrine”;
(lxiii)
by inserting after the item “Rasburicase” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Ravidasvir
-
All preparations”;
P.U. (A) 306 58
(lxiv)
by inserting after the item “Rizatriptan; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Robenacoxib
-
All preparations”;
(lxv)
by inserting after the item “Sacubitril” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Safinamide
-
All preparations”;
(lxvi)
by inserting after the item “Saquinavir; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Sarolaner
-
All preparations”;
(lxvii)
by deleting the item “Sodium edetate” and the particulars relating to it;
P.U. (A) 306 59
(lxviii)
by inserting after the item “Sodium hydroxide” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Sodium zirconium cyclosilicate
-
All preparations”;
(lxix)
by inserting after the item “Tadalafil” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tafamidis
-
All preparations”;
(lxx)
by inserting after the item “Tafluprost” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Talazoparib
-
All preparations”;
P.U. (A) 306 60
(lxxi)
by inserting after the item “Tetramisole” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tetrofosmin
-
-
All preparations for parenteral administration
-
-
All preparations unless in Group C”;
(lxxii)
by inserting after the item “Toltrazuril” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tolvaptan
-
All preparations”;
(lxxiii)
by inserting after the item “Valaciclovir; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Valbenazine
-
All preparations”;
P.U. (A) 306 61
(lxxiv)
by inserting after the item “Verapamil; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Vericiguat
-
All preparations”;
(lxxv)
by substituting for the item “Zinc p-phenolsulphonate” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Zinc p-phenolsulphonate
-
-
Medicinal preparations unless exempted
All preparations other than
Group C and exempted
-
Strength of 5%
and under”;
(lxxvi)
by substituting for the item “Zipeprol; its salts” the item “Zipeprol”; and
(lxxvii)
by substituting for the item “Zolpidem; its salts” the item “Zolpidem”; and
P.U. (A) 306 62
(i)
in the list of “Anaesthetics:”—
by inserting after the item “Desflurane” the item “Diphenidine”;
by inserting after the item “Methoxetamine (MXE)” the item “3-Methoxyphencyclidine (3-MeO-PCP)”; and by substituting for the item “Phencyclidine; its salts” the item “Phencyclidine”;
(ii)
in the list of “Analeptics and Central Stimulants:”—
by substituting for the item “N-Ethylamphetamine; its salts” the item “Ethylamphetamine”;
by inserting after the item “Etryptamine (DD)” the item “Eutylone (DD)”;
by substituting for the item “Lefetamine or SPA or (-)-1-dimethyl-amino-1, 2-diphenylethane” the item
“Lefetamine”;
by inserting after the item “4-Methylbuphedrone” the item “Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) (DD)”;
P.U. (A) 306 63
by substituting for the item “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-
methylbutanoate (AMB-FUBINACA)” the item “Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)”;
by substituting for the item “Methylphenidate; its salts” the item “Methylphenidate”;
by substituting for the item “Pemoline; its salts” the item “Pemoline”; and by substituting for the item “Pipradrol; its salts” the item “Pipradrol”;
(iii)
in the list of “Analgesics including antipyretic and anti-inflammatory agents:”—
by substituting for the item “Buprenorphine; its salts” the item “Buprenorphine”;
by inserting after the item “Glaphenine” the item “Grapiprant”;
by substituting for the item “Nalbuphine; its salts” the item “Nalbuphine”;
by substituting for the item “Pentazocine; its salts” the item “Pentazocine”; and by inserting after the item “Rizatriptan; its salts” the item “Robenacoxib”;
P.U. (A) 306 64
(iv)
in the list of “Anorectics:”—
by substituting for the item “Amfepramone; its salts” the item “Amfepramone”;
by substituting for the item “Aminorex; its salts” the item “Aminorex”;
by substituting for the item “Benzphetamine; its salts” the item “Benzphetamine”;
by substituting for the item “Phendimetrazine; its salts” the item “Phendimetrazine”;
by substituting for the item “Phenmetrazine; its salts” the item “Phenmetrazine”;
by substituting for the item “Phentermine; its salts” the item “Phentermine”; and by substituting for the item “Propylhexedrine; its salts” the item “Propylhexedrine”;
(v)
in the list of “Anticholinergics:”, by inserting after the item “Propantheline; its salts” the item “Propiverine”;
(vi)
in the list of “Anticonvulsants:”, by inserting after the item “Beclamide” the item “Cannabidiol”;
(vii)
in the list of “Antineoplastic agents and Immunosuppressants:”—
P.U. (A) 306 65
by inserting after the item “Abiraterone” the item “Acalabrutinib”;
by inserting after the item “Atezolizumab” the item “Avelumab”;
by inserting after the item “Capecitabine” the item “Capmatinib”;
by inserting after the item “Carmustine; its salts” the item “Casirivimab”;
by inserting after the item “Durvalumab” the item “Entrectinib”;
by inserting after the item “Idelalisib” the item “Imdevimab”;
by inserting after the item “Pazopanib” the item “Pegaspargase”;
by inserting after the item “Sarilumab” the item “Satralizumab”; and by inserting after the item “Tacrolimus” the item “Talazoparib”;
(viii)
in the list of “Antiparkinsonism agents:”, by inserting after the item “Rotigotine” the item “Safinamide”;
P.U. (A) 306 66
(ix)
in the list of “Antiviral agents:”—
by inserting after the item “Interferons” the item “Labuvirtide”;
by inserting after the item “Methisoprinol” the item “Molnupiravir”;
by inserting after the item “Nevirapine; its salts” the item “Nirmatrelvir”;
by inserting after the item “Pibrentasvir” the following items:
“Ravidasvir
Regdanvimab”; and by inserting after the item “Sofosbuvir” the item “Sotrovimab”;
(x)
in the list of “Cardio drugs:”—
by inserting after the item “Oxprenolol; its salts” the item “Pimobendan”; and by inserting after the item “Tirofiban” the item “Vericiguat”;
P.U. (A) 306 67
(xi)
in the list of “Dermatological agents:”, by inserting after the item “Methoxsalen” the item “Oclacitinib”;
(xii)
in the list of “Diuretics:”, by inserting after the item “Spironolactone” the item “Tolvaptan”;
(xiii)
in the list of “Hallucinogens:”—
by substituting for the item
“2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25B-NBOMe)”
the item
“2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25B-NBOMe) (DD)”;
by substituting for the item
“2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25C-NBOMe)”
the item
“2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25C-NBOMe) (DD)”; and by substituting for the item
“2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25I-NBOMe)”
the item
“2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25I-NBOMe) (DD)”;
P.U. (A) 306 68
(xiv)
in the list of “Hypnotics and sedatives:”—
by substituting for the item “Barbituric acid and other substances structurally derived therefrom;
their compounds; their salts” the item “Barbituric acid”;
by inserting after the item “Hexapropymate” the item “Lemborexant”; and by substituting for the item “Zolpidem; its salts” the item “Zolpidem”;
(xv)
in the list of “Industrial and laboratory poisons:”, by substituting for the item “Piperidine” the item “Piperidine unless specified elsewhere in the List”;
(xvi)
in the list of “Narcotics:”—
by inserting after the item “(DD) 4-bromo-2, 5-dimethoxyphenethylamine (2C-B)” the item “(DD) Brorphine”;
by inserting after the item “(DD) Isomethadone” the item “(DD) Isotonitazene”; and by inserting after the item “(DD) 1-Methyl-4-phenyl-4-piperidinol propionate (MPPP)” the item
“(DD) Metonitazene”;
P.U. (A) 306 69
(xvii)
in the list of “Tranquillisers:”—
by inserting after the item “Benzoctamine; its salts” the item “1,4-Benzodiazepine unless specified elsewhere in the List”;
by deleting the item “Diazepam and other substances structurally derived from 1, 4-benzodiazepine;
their salts, unless specified elsewhere in the List”;
by inserting after the item “Hydroxyzine; its salts” the item “Lurasidone”; and by inserting after the item “Tybamate” the item “Valbenazine”; and
(xviii)
in the list of “Miscellaneous:”—
by inserting after the item “Brucine” the following items:
“Burosumab
Tert-Butyl 4-
(phenylamino)piperidine-1-carboxylate (1-boc-4-AP)”;
by inserting after the item “Disodium clodronate” the item “Disodium edetate”;
P.U. (A) 306 70
by inserting after the item “Ergot, alkaloids of” the item “Esafoxolaner”;
by inserting after the item “Fampridine” the item “Faricimab”;
by inserting after the item “Imiquimod” the item “Inclisiran”;
by inserting after the item “Lung phospholipid” the item “Luspatercept”;
by deleting the item
“Methyl(2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-
methylbutanoate (FUB-AMB) (DD)”;
by inserting after the item “Nitrophenols, ortho, meta and para” the following items:
“Norfentanyl
Nusinersen”;
by inserting after the item “Pegvisomant” the item “Pemafibrate”;
(J)
by inserting after the item “Pentosan” the item “5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (CUMYL-PEGACLONE)(DD)”;
P.U. (A) 306 71
(K)
by inserting after the item “Phenols (any member of the series of phenols of which the first member is phenol and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” the item “N-Phenyl-4-piperidinamine (4-AP)”;
(O)
by inserting after the item “Sodium cromoglycate” the item “Sodium zirconium cyclosilicate”;
(Q)
by inserting after the item “Teriparatide” the item “Tetrofosmin”.
Made 13 September 2023
[KKM.600-18/2/95; PN(PU2)172/JLD. 20]
DR. ZALIHA BINTI MUSTAFA
Minister of Health
Common questions
- What is PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023?
- PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 is Malaysia P.U. (A), cited as P.U. (A) 306 2023, currently marked in force and first recorded in 2023.
- Is PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 still in force?
- Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 is currently in force.
- When did PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 take effect?
- PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 was first recorded in 2023.
- How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 have?
- PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 contains 2 sections.
- Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023?
- The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2023 is published at lom.agc.gov.my.